Rheumatologic Dermatology Society (RDS) Annual Meeting
Saturday, November 7, 2015 8am to 5pm
Mission Bay Conference Center at UCSF
Fisher Banquet Room West
1675 Owens Street, Suite 251 San Francisco, CA
AGENDA
8-8:30Continental breakfast (Fisher Banquet Room East)
8:30-8:45Welcome
David Fiorentino (Stanford University)
8:45-9:30Update on the cutaneous lupus classification project
Joe Merola (Brigham and Women’s Hospital)
9:30-10The Vasculitis Clinical Research Consortium
Peter Merkel and Rob Micheletti (University of Pennsylvania)
10-10:15Break
Novel targets fortherapy in dermatomyositis
10:15-10:45Introduction
Jan Dutz (University of British Columbia)
10:45-11:15Interferons in dermatomyositis
Steve Greenberg (Brigham and Women’s Hospital)
11:15-11:30Activity of type I and type II interferons in dermatomyositis skin is correlated with characteristic pathologic features
Hayley Leatham, Kerri Rieger, Lorinda Chung, Shufeng Li, Brandon Higgs, Yihong Yao, KavitaSarin, David Fiorentino
Stanford University, Department of Dermatology
11:30-11:45The Janus kinase inhibitor tofacitinib is an alternative treatment option for refractory cutaneous dermatomyositis
Drew Kurtzman, Natalie Wright, Janice Lin, Alisa Femia, Henry Townsend, Mital Patel, Ruth Ann Vleugels
Brigham and Women’s Hospital, Department of Dermatology
12-1Lunch (Fisher Banquet Room East)
Cutaneous Lupus Erythematosus
1-1:15Activation of T-Follicular Helper Cells and B Cells in Ultraviolet Light-Induced Murine Model of Systemic Lupus Erythematosus
Misha Zarbafian, Mehran Ghoreishi, Jan Dutz
University of British Columbia, Department of Dermatology
1:15-1:30Immunohistochemical characterization of acute and chronic
discoid lupus erythematosus skin lesions
Jack C. O’Brien, Gregory A. Hosler, Benjamin F. Chong, MD
University of Texas, Southwestern, Department of Dermatology
1:30-1:45Belimumab for the treatment of recalcitrant cutaneous lupus –
a pilot project
Priyanka Vashisht, ManpreetSethi, Melanie Rohr, Debbie Lim, Michelene Hearth-Holmes
University of Nebraska Medical Center, Division of Rheumatology
Paraneoplastic skin disease
1:45-2Myelodysplastic syndrome presenting as generalized
granulomatous dermatitis
Samuel J. Balin, David A. Wetter, Paul J. Kurtin, Louis Letendre, Mark R. Pittelkow
Mayo Clinic, Department of Dermatology
2-2:15Evidence-Based Malignancy Screening in patients with Dermatomyositis
Anthony P. Fernandez, FabrizioGalimberti, Yumeng Li
Cleveland Clinic, Department of Dermatology
2:15-2:30Outcomes of malignancy screening practices fordermatomyositis: data from two U.S. cohorts
Hayley Wheeler, Courtney Schadt, Sarah Chisolm, Deborah Fretwell, Lorinda Chung, Jeffrey Callen, David Fiorentino
Stanford University, Department of Dermatology
University of Louisville, Division of Dermatology
Morphea
2:30-2:45Changes of disease activity and damage over time in morphea
Patients
Jack C. O’Brien and Heidi T. Jacobe
University of Texas, Southwestern, Department of Dermatology
2:45-3Epidemiology and treatment of post-irradiation morphea: a
retrospective analysis from three large tertiary care centers
Renee Fruchter,Drew Kurtzman, Daniel R. Mazori, Natalie A. Wright,
Mital Patel, Ruth Ann Vleugels, Alisa N. Femia
Brigham and Women’s Hospital, Department of Dermatology
New York University, Department of Dermatology
3-3:15Break
Instruments for skin assessment in dermatomyositis
3:15-3:30Evaluation of the Reliability and Validity of the Cutaneous
Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Assessment Tool-Binary Method (CAT-BM) Among
Pediatric Dermatologists, Rheumatologists, and Neurologists in
Juvenile Dermatomyositis
Janice Tiao, Neelam Khan, Rui Feng, Emily M. Berger, John Brandsema,
Carrie C. Coughlin, Elizabeth A. Kichula, Melissa A. Lerman, Svetlana
Lvovich, Patrick J. McMahon, Lisa G. Rider, Adam I. Rubin, Lisabeth V.
Scalzi, Douglas M. Smith, Alysha J. Taxter, James R. Treat, Sabrina W.
Yum, Joyce Okawa, Victoria P. Werth
University of Pennsylvania, Department of Dermatology
3:30-3:45The Cutaneous Dermatomyositis Disease Area and Severity Index
as a primary efficacy endpoint in a Phase 2 clinical trial of IMO-
8400 in patients with dermatomyositis
David Fiorentino, Mark Hurtt, Julie Brevard, Victoria Werth
Stanford University, Department of Dermatology
IDERA Pharmaceuticals, Inc.
University of Pennsylvania, Department of Dermatology
Misc
3:45-4Good Syndrome - An adult onset immunodeficiency associated
withautoimmunity
Jan Dutz
University of British Columbia, Department of Dermatology
4-4:30Website update
4:30-5RDS business meeting
Nominations and membership: Nicole Fett (Oregon Health Sci U)
Amendments to bylaws: David Fiorentino (Stanford)
Other business